Cargando…
The Incidence, Risk Factors, and Outcomes With 5-Fluorouracil–Associated Coronary Vasospasm
BACKGROUND: Coronary vasospasm is a recognized side effect of 5-fluorouracil (5-FU). There are limited and conflicting data on the incidence, risk factors, and prognostic effect of 5-FU–associated vasospasm. OBJECTIVES: This study sought to assess the incidence, risk factors, and prognostic implicat...
Autores principales: | Zafar, Amna, Drobni, Zsofia D., Mosarla, Ramya, Alvi, Raza M., Lei, Matthew, Lou, Uvette Y., Raghu, Vineet K., Murphy, Sean P., Jones-O’Connor, Maeve, Hartmann, Sarah, Gilman, Hannah K., Weekes, Colin D., Clark, John R., Clark, Jeffrey, Blaszkowsky, Lawrence, Tavares, Erica, Neilan, Tomas G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8018593/ https://www.ncbi.nlm.nih.gov/pubmed/33817666 http://dx.doi.org/10.1016/j.jaccao.2020.12.005 |
Ejemplares similares
-
The efficacy and safety of cardio-protective therapy in patients with 5-FU (Fluorouracil)-associated coronary vasospasm
por: Zafar, Amna, et al.
Publicado: (2022) -
Association between incidental statin use and skeletal myopathies in patients treated with immune checkpoint inhibitors
por: Drobni, Zsofia D, et al.
Publicado: (2021) -
Pre-Existing Autoimmune Disease Increases the Risk of Cardiovascular and Noncardiovascular Events After Immunotherapy
por: Lee, Charlotte, et al.
Publicado: (2022) -
Pericardial disease in patients treated with immune checkpoint inhibitors
por: Gong, Jingyi, et al.
Publicado: (2021) -
Decreased Absolute Lymphocyte Count and Increased Neutrophil/Lymphocyte Ratio With Immune Checkpoint Inhibitor–Associated Myocarditis
por: Drobni, Zsofia D., et al.
Publicado: (2020)